Literature DB >> 35962905

Prognostic values of distal ureter involvement and survival outcomes in bladder cancer at T1 and T2 stages: a propensity score matching study.

Song Xiao1, Xiangpeng Zhan1, Tao Chen1, Jingxin Wu1, Linhao Xu1, Ming Jiang1, Wen Deng1, Ke Zhu1, Zhenhao Zeng1, Xiaofeng Cheng1, Qiang Zhou1, Wei Huang1, Xiaochen Zhou1, Cheng Zhang2, Bin Fu3, Gongxian Wang4.   

Abstract

PURPOSE: To study prognostic values of distal ureter involvement (DUI) and survival outcomes in bladder cancer at T1 and T2 stages.
METHODS: The national Surveillance, Epidemiology, and End Results database (2004-2015) was applied to obtain bladder cancer patients. We used the Kaplan-Meier method with the log-rank test, subgroup analyses, the multivariable Cox proportional hazard model and propensity score matching (PSM).
RESULTS: A total of 490 patients with DUI and 28,498 patients with non-DUI (non-involvement) were enrolled in our study. After 1:1 PSM, 490 matched pairs were picked out. The multivariable Cox regression before and after PSM revealed that the DUI group had a high risk of overall mortality (HR = 1.374, P < 0.001 before PSM; HR = 1.513, P < 0.001 after PSM) and cancer-specific mortality (HR = 1.632, P < 0.001 before PSM; HR = 1.699, P < 0.001 after PSM). The results of survival analyses showed that patients in the DUI group had lower survival probability in OS (P = 0.0011) and CSS (P < 0.0001) analyses. Nevertheless, in the subgroup analysis, significant differences were only observed in the T1 stage in terms of CSS and T2a stage in terms of OS and CSS (all P < 0.05).
CONCLUSION: The prognosis of DUI was poorer than that of non-DUI. DUI was an independent risk factor for OM and CSM in bladder cancer at T1 and T2 stages especially for those at T1 and T2a stages.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Distal ureter involvement; Prognosis; SEER database; Survival; Urinary bladder

Year:  2022        PMID: 35962905     DOI: 10.1007/s11255-022-03260-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  15 in total

1.  Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) urological tumour registry.

Authors:  Gregory B Boustead; Sarah Fowler; Rajiv Swamy; Roger Kocklebergh; Luke Hounsome
Journal:  BJU Int       Date:  2014-01-22       Impact factor: 5.588

2.  Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.

Authors:  Eric Chieh-Lung Chou; Alex T Lin; Kuang-Kuo Chen; Luke S Chang
Journal:  Int J Urol       Date:  2006-06       Impact factor: 3.369

3.  Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?

Authors:  Bjoern G Volkmer; Thomas Schnoeller; Rainer Kuefer; Kilian Gust; Florian Finter; Richard E Hautmann
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

4.  Resection of the Intramural Portion of the Distal Ureter during Transurethral Resection of Bladder Tumors: Predictive Factors for Secondary Stenosis and Development of Upper Urinary Tract Recurrence.

Authors:  Oscar Rodriguez Faba; J M Gaya; Alberto Breda; Pablo Juarez Del Dago; Francesca Pisano; Daniel Salas; Juan Palou
Journal:  J Urol       Date:  2016-01-21       Impact factor: 7.450

Review 5.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.

Authors:  Sebastien Antoni; Jacques Ferlay; Isabelle Soerjomataram; Ariana Znaor; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

6.  Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis.

Authors:  Jonathan L Wright; James Hotaling; Michael P Porter
Journal:  J Urol       Date:  2009-01-16       Impact factor: 7.450

Review 7.  Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments.

Authors:  Kristin M Sanderson; Morgan Rouprêt
Journal:  BJU Int       Date:  2007-04-08       Impact factor: 5.588

Review 8.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Authors:  Marko Babjuk; Maximilian Burger; Eva M Compérat; Paolo Gontero; A Hugh Mostafid; Joan Palou; Bas W G van Rhijn; Morgan Rouprêt; Shahrokh F Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José Luis Dominguez Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup
Journal:  Eur Urol       Date:  2019-08-20       Impact factor: 20.096

9.  Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer.

Authors:  Laura Lorenzo Soriano; Guzmán Ordaz Jurado; José Luis Pontones Moreno; Sara Villarroya Castillo; Soraya Hernández Girón; Iván Sáez Moreno; David Ramos Soler
Journal:  Urology       Date:  2019-04-12       Impact factor: 2.649

10.  Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.

Authors:  Man Shen; Jiajia Zhang; Ran Tang; Yuhao Wang; Xiaokai Zhan; Sibin Fan; Zhongxia Huang; Yuping Zhong; Xin Li
Journal:  Cancer Med       Date:  2021-10-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.